Podcast appearances and mentions of scott friedman

A multi-platinum songwriter who combines humor, wisdom and inspiration with soaring vocals and acoustic arrangements to give her audiences a “faith-lift.”  Jana is the founder of Together For Good Worldwide and Refugee Film School as well as the co-founder of Together We Can Change the World.  Her songs have been featured on television shows like 20/20, Entertainment Tonight, and Oprah, and movie soundtracks, sung by Reba McEntire and others. While her compositions were climbing the music charts, often sung by other artists, Jana was charting a different path. With a background in TV journalism, music, and stand-up comedy, Jana turned her concerts into Keynote Concerts, becoming a Certified Speaking Professional with two TEDx performances in addition to two concerts at Carnegie Hall. Jana Stanfield has delivered her Keynote Concerts in the United States, Canada, South Africa, Kenya, the Bahamas, Australia, New Zealand, India, England, the Netherlands, Dubai, Lebanon, Turkey, Greece, Spain, France, Cambodia, Thailand, Malaysia, Myanmar, the Philippines, Bali and Singapore.  Her TEDx talks were at NASA, and then in Chennai, India. To help girls without access to school, she and her professional speaking colleague, Scott Friedman, co-founded an international 501c3 called Together We Can Change the World, www.TWCCTW.com , with more than 15 projects in 5 countries to empower disadvantaged women and girls with education and job skills. She now lives in Bali, Indonesia, where she performs her music and humor. 

- Grief - You know how I know you are misinformed? - You are anti-woke and anti-cancel culture yet you want to cancel things. You call everything “fake news” you don't agree with and……You believe Elon Musk is canceling The View and you applaud that but also don't realize it's a fake news story. Source - The real stock market. - Isn't the stock market a scam because instead of working class people making more money for pay the get an incentive based on how good a company performs, and also their funds are tied up into stocks for large corporations who can use the investments of working class people to create more wealth for the bigger corporations which prices the retail investors out of more things in the economy? - The Dems are far from innocent. BUT there's a difference between corruption and a fascist dictator. - Texas/climate change/insurance - yeah the 3 aren't going together. - "As climate change fuels a stark increase in extreme weather, it is also driving up the cost of homeowner's insurance. In recent decades, Texas has seen more billion-dollar disasters than any other state, causing the price of homeowner's insurance premiums there to skyrocket. Scott Friedman, senior investigative reporter at NBC's owned station in Dallas-Fort Worth, has more." - Source - The BROilgarchs - "Among the broligarchs' defining traits is an undemocratic conviction, made explicit by some, that their ideas should prevail regardless of the preferences of their fellow citizens. “Competition is for losers,” the headline of a 2014 Thiel op-ed in The Wall Street Journal declared—a sentiment that extends to the competition of ideas and policies on which democracy depends. - Source - Operation ABSCAM - On February 2, 1980, the world learned of our high-level investigation into public corruption and organized crime, infamously code-named ABSCAM. Individuals caught on tape in the FBI's ABSCAM investigation, a high-level undercover sting targeting public corruption and organized crime. - Source This episode is sponsored by Joe Ugly Apparel - ⁠⁠⁠www.JoeUglyApparel.com⁠⁠⁠ Stylish, bold, & modern apparel. For the rare misfit. Be something different. Be a misfit. Joe Ugly Apparel If you or anyone you know is looking for podcast editing, podcast production, or any other podcast services reach out to The Wild 1 Media. Produced by The Wild 1 Media. ⁠⁠⁠www.thewild1media.com⁠⁠⁠ ⁠⁠⁠https://darksidediaries.sounder.fm⁠⁠⁠ ⁠⁠⁠https://anchor.fm/ttmygh⁠⁠⁠ ⁠⁠⁠https://crypto101.sounder.fm/

Inside the two-year fight to bring charges against school librarians in Granbury, TexasNBC News, By Mike Hixenbaugh, Tyler Kingkade, Scott Friedman and Eva Parks, on July 23, 2024https://www.nbcnews.com/news/us-news/school-librarians-banned-books-investigation-texas-rcna161444In a saga reminiscent of the Keystone Cops, a two-year pursuit of felony charges against school librarians in Granbury, Texas, unfolded like a farcical mission gone awry. Right-wing extremist Scott London embarked on a vendetta, pouring over stacks of literature while sporting a body cam to capture his quest to persecute—er, prosecute—three school librarians. Their alleged crime? Allowing minors to check out books deemed obscene. Despite subpoenas and dramatic investigative theatrics, the case ultimately fizzled when the district attorney declined to indict, citing insufficient evidence.Scott London's mission to stop kids from reading books he deemed inappropriate was both absurd and alarming. The details of his crusade, covered by NBC News through the reporting of Mike Hixenbaugh, Tyler Kingkade, Scott Freeman, and Nia Parks on July 23, 2024, reveal a tale of overreach and misplaced zeal.The debate over who should decide which books belong in schools or libraries was reignited by this case. Cindy, a commentator on the issue, argued that self-righteous individuals like London, who have nothing better to do than invade privacy and push their own beliefs, should not make such decisions. Instead, she suggested that the Ministry of Education, funded and managed at the federal level, should handle these matters to ensure uniformity and fairness across states.London's antics included gathering a list of children who had checked out the contentious books, ironically in the name of creating a safe environment for them. His efforts highlight a broader issue: a segment of the population views education and access to diverse ideas as threats. This mindset, according to Cindy, stems from discomfort with topics like gender and homosexuality, which London finds "icky" and thus seeks to ban from public discourse.Eli, another commentator, emphasized that banning books only makes them more appealing to children. If a book is removed from a library, kids will find ways to access it, often through other means like purchasing it online. This approach does nothing to stop children from reading the material and instead punishes educators and librarians who aim to provide a comprehensive education.The discussion also touched on the racial aspects of book banning. Books by and about people of color are frequently targeted, reflecting a discomfort with confronting historical and contemporary issues of race in America. Cindy noted that the shame associated with America's racist past leads to an avoidance of these topics, resulting in efforts to erase them from educational materials.The case of Scott London's failed prosecution of librarians in Granbury, Texas, serves as a stark reminder of the ongoing battle over educational content and the dangers of allowing personal biases to dictate public policy. It also underscores the need for a more mature and equitable approach to managing school libraries and the materials they offer to students. The Non-Prophets, Episode 23.31.2 featuring Infidel64, Cindy Plaza, Eli Slack and Kelley LaughlinBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-non-prophets--3254964/support.

Scott Friedman, a stand-up comedian, shares his experiences and upcoming shows in this conversation with Meg. Scott talks about his background in real estate, insurance, and radio, and how he transitioned into stand-up comedy. He discusses his upcoming performances at various venues, including Eastlyn Golf Club and the Savoy, and highlights the importance of drawing on personal life experiences for his comedy material. He talks about booking gigs, managing his own schedule, and the importance of adapting his material to different venues. Scott also shares his inspirations in comedy and highlights some of the comedians he enjoys working with. He discusses how he got started in stand-up comedy and the role it plays in his life alongside his full-time job in real estate and insurance. Scott encourages listeners to come see his shows and shares his contact information for bookings. Takeaways Scott Friedman has a diverse background in real estate, insurance, and radio before transitioning into stand-up comedy. He draws on personal life experiences, such as his heart attack and dating as a 53-year-old, for his comedy material. Scott will be performing at various venues, including Eastlyn Golf Club and the Savoy, where he promises a fun and entertaining show. Tickets for his shows can be purchased through the respective venues' websites or by calling for reservations. Stand-up comedy gigs are often small and not financially lucrative, so having a manager may not be worth it for many comedians. Comedians need to adapt their material to different venues and audiences, and they often receive guidelines or ratings from the venue regarding appropriateness. Scott Friedman enjoys working with comedians like Jay Black and Mike Egan, who are highly skilled and respected in the industry. Scott got started in stand-up comedy during college and continued performing after a long break, finding joy in making people laugh. Scott can be contacted for bookings or inquiries at comedyscott@gmail.com. Upcoming Comedy Shows at Eastlyn Golf Club and the Savoy From Real Estate to Stand-Up Comedy: Scott Friedman's Journey Adapting Material and Booking Gigs Getting Started in Stand-Up Comedy "I draw on the fact that I'm 53 years old and I'm dating. Oh, that's fun, right?" "I have about four shows coming up in the next month. I'm only on the flyer for one of them." "It's a synagogue in Wildwood. I think it's Beth not a religious show though." "In the lovely world of stand-up comedy, it doesn't matter until you become a star." "I do it for the fun of it." "Comedians need to adapt their material to different venues and audiences." `Chapters 00:00 Introduction and Background 02:40 Upcoming Comedy Shows in Cumberland County 03:45 New Chapter 05:28 The Challenges of Being a Comedian 08:01 Drawing on Personal Life Experiences for Comedy 17:03 The Challenges of Booking Gigs as a Comedian 18:44 The Joy of Performing Stand-Up Comedy 19:44 Inspirations and Favorite Comedians 20:31 Adapting Routines for Different Venues 22:13 Balancing a Full-Time Job and Comedy Career 24:20 The Camaraderie of Working with Other Comedians

On April 23, the global MASLD community lost one of its giants when SurfingMASH Co-founder Stephen Harrison passed away unexpectedly. Co-hosts Louise Campbell and Roger Green and guests Jeff McIntyre and Mike Betel each share a memory of Stephen. Jeff McIntyre starts this conversation by remembering Stephen as a fellow Southerner and, in addition to his many professional accomplishments, a person who could cut through high-level discussions with a "pithy little West Texas saying" that would make a complex or abstract concept clear. Mike Betel starts his comments by talking about Stephen's older brother, Ken, who wrote personal messages back to every comment he could find on social media, which was a remarkable task in its own right. Mike discusses how often he heard Stephen speak and how many times he interviewed Stephen for various Fatty Liver Alliance posts or events. Mike concludes with a story about Stephen talking for five minutes while Mike's audio was malfunctioning and then doing a second take remarkably similar to the first. Louise discusses being on the podcast with Stephen for years and regrets that he will never cook her a deep-fried turkey. She recalls his hobby of building elaborate sand structures on the beach with his family while he ran around the world, putting a large dent in MASLD. Roger starts by describing the first time he saw Stephen at NASH-TAG 2019 and how his larger-than-life presence and exceptional energy suffused a room of 200 people. He continues by using a favorite "Harrisonism" about being thankful that they didn't stop after WD-39 because WD-40 was the 40th effort to create the product we know today, and comments that for Stephen as Principal Investigator, Rezdiffra was his WD-40. Finally, Roger says he "just lost it" when reading the Walt Whitman poem "O Captain, My Captain," which Scott Friedman posted on LinkedIn as a tribute to Stephen.After the personal comments, Roger says that next week's episode will be a tribute to Stephen from some of his closest friends in the global MASLD community.

#56 - Every so often we need a blast of motivation to stick with our goals.  Today is the day!My guest, Scott Friedman, is a certified personal trainer and coach.  He's here to talk about creating a positive mindset to change your thoughts and habits.  Topics covered include:*How to use motivation to become disciplined*Why do people fail at achieving their goals and how you can avoid failure*How to shape your perspective to create the life that you want*How to use momentum as a tool for achieving successBe sure to check out Scott's podcast, The Power of Progress.  Visit him at scottspeaksfitness.com and follow him on Instagram.Follow me on Instagram @barry_s_karch

Does losing weight and, more importantly, losing fat feel impossible no matter how hard you try? Have you ever lost 10 pounds only to gain back 15? Do you dread stepping on the scale because it never seems to budge?If you can't figure out why the formula works for others but not you, this co-created and co-hosted episode breaks down the real reasons you haven't been seeing results.Join Philip (@witsandweights) and his special co-host today, Scott Friedman,  as they lift the curtain on common weight loss mistakes and provide actionable solutions. You'll walk away ready to troubleshoot plateaus, optimize body composition, and create a plan that finally helps you shed fat for good.Scott Friedman (@scottfriedman24) is the host of The Power of Progress podcast. Scott bridges fitness and mindset with his podcast, aiming to end self-sabotage in fitness routines, inspire consistency, and promote a healthier lifestyle. His podcast dismisses fad diets, magic pills, and best routines, focusing instead on personal growth and the journey towards better health.Today, you'll learn all about:3:29 Narrative shift: Fat loss vs. weight loss6:47 Understanding the road ahead (pitfalls)9:06 Restrictive diets vs. flexible dieting (the hamster wheel of diet)14:50 Uninformed optimism or  informed pessimism19:56 Not tracking or inaccurate tracking, and intuitive eating 31:00 Top 5 foods that have hidden calories41:56 Giving up too quickly and overcoming plateaus49:53 Too aggressive with the rate of loss55:20 Understanding what ‘hard' feels like and getting discouraged1:01:16 Not prioritizing hunger management: not enough fiber 1:08:51 Not moving enough 1:10:58 Not training with enough load or "intensity"1:16:28 Cardio for fat loss1:19:39 Not sleeping enough, too much stress, or too much medium/high-intensity cardio1:26:25 OutroEpisode resources:Scott's podcast: The Power of Progress IG: @scottfriedman24Youtube: @powerofprogressWebsite: scottspeaksfitness.com

Struggling with fat loss can feel like a solo journey through a maze with no exit in sight, but what if you had a map and TWO companions to guide you through? Announcing an exciting FIRST for the podcast that you're going to love...on today's Quick Wits.Prepare to learn why some breeze through their fat loss journey while others hit wall after wall, and how understanding the nuances between fat and weight loss can make all the difference.Listen to the episode and then...The Power of Progress hosted by Scott Friedman (follow it now!)...and if you missed it...If you want to build as much muscle as possible without wasting time, join our upcoming free LIVE training on Friday March 1 (link below).Even if you can't go live, you'll get the replay and bonus

Don't miss this comprehensive episode of the "Neuroscience Meets Social and Emotional Learning" podcast, where leadership guru and bestselling author, Grant 'Upbeat' Bosnick, discusses powerful tactics from his latest book for mastering self-awareness and personal transformation. Bosnick, recognized by reputable figures such as Scott Friedman and Marshall Goldsmith, presents his unique combination of neuroscience research and practical wisdom with a focus on self-improvement and growth. Watch on YouTube here https://youtu.be/vGweJ0sCJ14 The episode dissects the concepts of his award-winning book "Tailored Approaches to Self-Leadership," illustrating how change and improvement are truly achievable both from internal ('inside out') and external ('outside in') perspectives. Listeners will grasp the immense power of self-leadership and its transformative effect on personal growth and success. Explore practical strategies for habit formation, the significance of sequentially reading chapters, and the impact of a self-assessment system. Gain insights from Grant's expert advice on maintaining a balance between strengths and weaknesses while chasing after your goals. Dive into the information-rich conversation that uncovers the art of learning and the fascinating intricacies of engaging the mind with real-time applications of knowledge. Ultimately, embark on an intellectual journey that has the power to elevate personal achievement and self-awareness to uncharted levels. Round-off this enlightening experience with the rich resources that Grant provides, from beautifully illustrated maps to enhance tracking of personal growth, to video series and companion workbooks designed for tailoring self-leadership strategies. So, ready yourself for a transformative journey of the mind into the world of self-leadership with this gripping episode. On today's episode #321 with Guest: Grant ‘Upbeat' Bosnick “Tailored Approaches to Self-Leadership: A Bite Size Approach Using Psychology and Neuroscience” we will cover: ✔ Powerful tactics from this NEW award-winning book that illustrates how change and achievement are truly achievable both from internal ('inside out') and external ('outside in') perspectives. ✔Listeners will grasp the immense power of self-leadership and its transformative effect on personal growth and success. ✔Explore practical strategies for habit formation, the significance of sequentially reading chapters, and the impact of a self-assessment system ✔Gain insights from Grant's expert advice on maintaining a balance between strengths and weaknesses while chasing after your goals ✔Embark on an intellectual journey that has the power to elevate personal achievement and self-awareness to uncharted levels. ✔Round-off this enlightening experience with the rich resources that Grant provides, from beautifully illustrated maps to enhance tracking of personal growth, to video series and companion workbooks designed for tailoring self-leadership strategies. Another example that shows us that failure is not an option. Here's what Scott Friedman, the author of Celebrate! Lessons Learned from the World's Most Admired Organizations has to say about the book we are going to cover today: Today's episode really is going to be a journey of the mind… Welcome back to SEASON 11 of The Neuroscience Meets Social and Emotional Learning Podcast, where we connect the science-based evidence behind social and emotional learning and emotional intelligence training for improved well-being, achievement, productivity and results—using what I saw as the missing link (since we weren't taught this when we were growing up in school), the application of practical neuroscience. I'm Andrea Samadi, an author, and an educator with a passion for learning and launched this podcast 5 years ago with the goal of bringing ALL the leading experts together (in one place) to help us to APPLY this research in our daily lives. On today's episode #321, we will be speaking with Grant ‘Upbeat' Bosnick[i], the Managing Director of YES (Your Empowering Solutions), author, consultant, keynote speaker and executive coach. He has worked with 100+ Fortune 500 and FTSE 100 companies to co-create people strategies to help organizations build a trusting, collaborative culture and develop leaders to transform their behavior to lead themselves, others and perform at a higher level. Originally from Toronto (where I grew up) and now based in Singapore, he has lived in Asia Pacific for over 20 years. When Grant reached out to me, earlier this month, it was not WHAT he said to me that caught my eye, but HOW he said it. Maybe because I was in the middle of writing the final part of our Science of Getting Rich book study, that's all about Thinking AND Acting in This Certain Way. Grant said that he uses “psychology and neuroscience, (and works) with Leaders and Teams in great organizations to go from human to superhuman, by tapping into the more resource-efficient parts of their brains, achieving more and being happier.” This sounds exactly like what I am trying to do for our listeners on this podcast, helping us to build stronger 2.0 versions of ourselves, and if Grant has some knowledge about how to do this, I want to know what he suggests, especially after all the high-level companies he has been working with over the past 20 years. I kept on reading what he had written in an email to me, and next I learned about his award-winning book, Tailored Approaches to Self-Leadership, that was published last year by Routledge, with a Foreword by Marshall Goldsmith.  “Marshall Goldsmith[ii] wrote the Foreword to his book?” I'm reading with a different lens now.  I don't know anyone in the field of leadership/coaching who doesn't know Marshall Goldsmith. He's known as the “World's #1 Leadership Thinker” with an unusual ability to help other people succeed. His mission in life to help successful leaders to get even better, so now I know the level that Grant Upbeat Bosnick has attained, before I've even read his book! Let's meet the author of Tailored Approaches to Self-Leadership and see if we can learn how to use this book as our guide in 2024, to apply neuroscience and psychology is a whole NEW way, taking us to the high levels of achievement expected by those who work with him, and those who work with those who he learned from like Marshall Goldsmith and the late Dr. Covey. Welcome Grant 'Upbeat' Bosnick! I'm looking forward to speaking with you today, and learning Intro Q: A book on leadership with a foreword written by Marshall Goldsmith! Before I ask you about your book, that's masterfully written, I wonder how did you cross paths with Marshall Goldsmith, “World's #1 Leadership Thinker” and how did he influence your work? The Foreword itself tells me about you before I've even read your book!  Q1: Then I read on to see all the others who have influenced you along the way, a couple of your influencers are mine (Dr. Stephen Covey) who we spoke about when we interviewed Greg Link, the co-founder of Covey Link, and Dr. Covey's long-time business partner from EP 207[iii] Can you share how Dr. Covey and others you mention have influenced your leadership journey?  ((This book is dedicated to all those who have influenced me to navigate my self-leadership journey: Marshall Goldsmith, Dr. Stephen R. Covey, Ken Blanchard, people close to me, among others; and to all of you reading this, to chart and navigate your personal self-leadership journey. May you choose your own leadership venture and transform your self.)) Q2: There's 18 chapters in the book, with each one exploring a different theme related to self-leadership and are written in such a way that we can read them in any order.  Q3: Can you explain how you picked the 18 leadership principles, and how do we now create change from the inside-out (using neuroscience/how our brain works) and outside-in (how we understand others and how others see us)?  How do you use practical activities, reflective questions personal anecdotes and Illustrations to help us to create change? Q3B: How did you create a map for this self-leadership journey? Q4: I think I'm answering my own questions here, but with the choose your own adventure theme, does it begin with the Self-Assessment[iv]? Q4A: Before we look at the tailored approach that was designed for me, I wonder if you can tell me off the top of your head, what areas YOU are focused on this year, and why? Q4B: Can we look at my Tailored Approach to Leadership to help others who listen, to know where they begin with their journey? Based on how I filled out the self-assessment, it pinpointed to me that Pathways 1 (goals/time management), 4 (physical health/emotion regulation) and 5 (change/resilience) are my lowest priorities.  I can tell you for sure these are carved into my daily habits (the highest importance for me with time management, health and pathway 5 seems to be hardwired into me, but these 3, I think I've got, so probably why they are showing up low. Pathway 2 (inspiration/motivation/influence/presence) is a high priority (100%) especially with the podcast, always looking for WHAT'S NEW and innovative that I can share/learn from and help others with, and Pathway 6 (relationships/authenticity, biases, trust, empathy) I know is also a high priority for me, with wanting to keep learning, interviewing high level guests, and helping us to take our results to the highest levels possible. Pathway 3, Mindfulness, Flow and Insight is of MEDIUM priority for me from the assessment. Like my low priority areas, I do think this one is important, and I also have time carved out daily for these, but I think the more interviews I'm doing, the more this leads to enhancing this area. Q4C: Once someone completes the self-assessment, how do they know which of the 18 chapters they should begin with? Just from lining up the chapters? For me, I skip Ch 2 (goals), and go straight to Ch 3 (inspiration and motivation?) Q4D: Before I even get to the book, how would you suggest I use this beautiful map you've drawn for me? It looks like the map outlines the book from Ch 1-18 starting with goals, and ending with resilience?  I like checking off things I've worked on…how do YOU use this colorful map? Q4E: I know I'm going to be focused on Pathway 2 (Motivation and Inspiration) but as I read Chapter 1 on goals, that was low priority for me, the science revealed something I've always wondered about. It was about the Force Field Driving Us according to Kurt Lewins Field Theory you mention in Chapter 2 on Goals. I'm always looking to connect science to some of the well-known books we've grown up studying (like Wallace D Wattles The Science of Getting Rich) who talks about taking action in our present environment.  As you take this action, you begin to change and will outgrow your present environment, preparing you for the NEW environment you will be moving towards.  Can you explain the science in the chapter on goals? How do we now create change from the inside-out (using neuroscience/how our brain works) and outside-in (how we understand others and how others see us) within each chapter? Do you think it's because you are making us think with the questions you ask us, and then point us in the direction of neuroscience? How do I know I've met with the change I set out to attain? Q5: For those out there who want to discover their own tailored approaches to leadership, (for themselves or their teams) what is the best route for them to take? Q6: Is there anything important Grant, that I've missed today? This book was much deeper than I realized when I started to see the neuroscience you've included, along with the activities included. For those who want to reach you, is the best place your website? I've listed your email, website, LinkedIn and YouTube below for people to find you. I want to thank you for the time you've taken to walk me through a very thorough Tailored Approaches to Self-Leadership that you've created in your book. I'm going to take the time to learn and implement each chapter, and am grateful to have had this opportunity to learn directly from you. Grant ‘Upbeat' Bosnick CONTACT grant@grantbosnick.com Website: https://grantbosnick.com/ LinkedIn:  https://www.linkedin.com/in/grantbosnick/ YouTube: https://www.youtube.com/@GrantBosnick Learn more about The Tailored Approach to Leadership Book https://grantbosnick.com/books/ Signature Keynotes and Solutions https://grantbosnick.com/signature-solutions/ RESOURCES: Self-Assessment for Grant Bosnick's book https://www.selfleadershipassessment.com/ Neuroscience Meets Social and Emotional Learning Podcast EPISODE #68 “The Neuroscience of Personal Change with Stephen R. Covey's The 7 Habits of Highly Effective People” https://andreasamadi.podbean.com/e/the-neuroscience-of-personal-change/ REFERENCES:   [i] http://grantbosnick.com/   [ii] https://marshallgoldsmith.com/   [iii] Neuroscience Meets SEL Podcast EP 207 with Greg Link https://andreasamadi.podbean.com/e/co-founder-of-coveylink-greg-link-on-unleashing-greatness-with-neuroscience-sel-trust-and-the-7-habits/   [iv] Self-Assessment for Grant Bosnick's book https://www.selfleadershipassessment.com/          

Thank you for tuning in to the MHS Podcast where we discuss how mindset change is one of the key ingredients to winning in better health and a better life with Scott Friedman! More on Scott below

This conversation between Scott Friedman, Laurent Castera, Louise Campbell and Roger Green covers what the panelists found exciting, important or striking about the presentations of clinical trial results at TLM2023.  Instead of focusing immediately on MASH drugs, Scott suggested we should not overlook the idea that elafibranor is preparing to come to market in the US as a novel medication for PBC with good efficacy and safety from patients who do not respond well to ursodiol or obeticholic acid. I note that elafibranor is only one of two PPARs speeding toward market in PBC with exciting data given what we all heard in the late-breaker presentation on seladelpar. Scott also mentions to integrin antagonist from Pliant in PSC, a disease with no available solutions today. Laurent agrees with Scott that the rare disease drug advances were more exciting than the advances in more common liver diseases.I bring up papers addressing the value of FGF-21 and FGF-19 agents in cirrhosis, which showed some promise for compensated cirrhotic patients. Scott politely disagrees, feeling that while these agents might hold disease steady, they do not address the challenges and mechanisms necessary to meaningfully regress disease. We agree there is a benefit to any agent that slows or reverses the course of disease even slightly in that this buys the patient more time to be treated with more exciting medications still in the pipeline. Scott notes that for Hepatitis C, a far simpler disease it took 25 years from discovery to cure on a path of incremental process. Scott notes that drug development successes are keeping investors interested, which is encouraging in a challenging environment for investment. Laurent returns to the issue of cirrhosis, noting that there are multiple challenges and concomitant bad behaviors like alcohol consumption. He points out that where good studies exist, these are short studies with small samples. Scott points out that MASH is less like hepatitis and more like inflammatory diseases like IBD, where causes of underlying disease are difficult to determine and there is no single pathway in drug development. He buttresses this by noting that in clinical trials, resmetirom provided benefit to only 25% of patients. 

This conversation between Scott Friedman, Laurent Castera, Louise Campbell and Roger Green covers what the panelists found exciting, important or striking about the presentations covering NITs, artificial intelligence and bariatric surgery at TLM2023. The conversation starts with Roger discussing a presentation in which Stephen Harrison shared HistoIndex data from the MAESTRO-NASH trial for resmetirom. HistoIndex's proprietary methods produced results suggesting 34% improvement in the placebo group vs. 54% in the treatment group. More interesting, Dean Tai from HistoIndex suggested to Roger in a private conversation that this 1/3 placebo success rate holds fairly common across trials using these methods. Given that bariatric surgery studies suggest a five-year gap from successful surgery to fibrosis regression, the one-year standard requested by FDA for conditional approval might lead us to understate drug efficacy for resmetirom and later New Drug Applications submitted under these criteria.Laurent discusses a study from Phillipe Mathurin's group in France that demonstrates among bariatric surgery patients, MASH resolution and fibrosis regression lead to improved outcomes. His point: it is important that this study confirms the idea that MASH resolution and fibrosis regression do, in fact, lead to fewer Major Adverse Liver Outcomes, or MALO.The conversation shifts to NITs and the value of biomarkers in proving that a drug is working. Laurent notes that no single market is sufficiently reliable and that we will need a cluster of tests to evaluate any given drug. As an example, he cites the impact of BMI on liver stiffness as a confounder that does not exist in other tests like ELF. Scott asks about HepQuant; Laurent has limited experience but finds the idea conceptually appealing. Scott notes that the slow rollout and low budget might be responsible for the lack of market and academic interest. Laurent focuses on a specific poster looking at a database of 16,000 patients over two years. The study shows that an increase in liver stiffness, AGILE-3 or AGILE-4 score all correlate with MALOs.  What the study doesn't address, and Laurent points up will be key to learn, is whether declines in these measures correlate with improved outcomes among declining patients. 

This conversation between Scott Friedman, Laurent Castera, Louise Campbell and Roger Green covers what the panelists found exciting, important or striking about liver science, VCTE, regulatory approvals using NITs or AI, and other issues at TLM 2023. It starts with Roger sharing his belief that regulators are likely to approve NITs only if a small battery of tests (or ideally, a single test) prove valuable in assessing all agents, or at least all agents, for a stage of disease or segment of the market. Scott notes his frustration that biopsy is an expensive and poorly-graded measure and hopes that FDA will move past semi-qualitative biopsy. Roger asks Scott what we learned about basic science in the meeting. Scott discusses advances in single-cell technologies as pivotal in helping us understand underlying disease better, and goes on to mention several presentations on senescent cells that provided insight but, he felt, little for basic drug development. Roger then asks Louise what in the meeting she found most interesting. She points to two posters regarding VCTE. The first looks at liver stiffness and controlled attenuation parameter, or CAP in patients after transplantation. Louise describes this as the first time she has seen CAP used as an independent predictor. She mentions a second poster on methotrexate using VCTE as having similar promise to expand VCTE as a research tool.Louise then goes on to discuss a poster addressing the evolving impact of allied providers in hepatology. In this poster, the authors projected a roughly 1/3 growth in hepatology patients by 2023 requiring treatment, coupled with a roughly 1/3 decline in the number of hepatologists available to treat them. Allied providers in hepatology showed a similar trend. To Louise, this signaled clearly that all countries need to boost the number of allied providers if these patients are to receive the care they will need. As the conversation winds down, Louise and Roger discuss the high level of patient presence and energy suffusing the entire event.

This conversation between Scott Friedman, Laurent Castera, Louise Campbell and Roger Green covers a pivotal session on the new MASLD nomenclature, plus what the panelists found exciting and important about the developing class of triple agonists, at TLM 2023. This conversation starts with Roger stepping gently into the topic of the new MASLD nomenclature by discussing a Saturday morning session chaired by Maru Rinella and Meena Bansal. The session took a broad, fairly detailed view of progress in knowledge and implementation of this nomenclature. Roger's point: two of the three obvious potential downsides to the new nomenclature are now rendered resolved. First, George Makar of FDA stated that the agency now uses the terms “MASH” and “NASH” or “MASLD” and “NAFLD” interchangeably, which means that the nomenclature will cause no delays or rework around drug and device clinical trials. Second, Quentin Anstee and Arun Sanyal reported from the LITMUS and NIMBLE databases that the patient overlap when mapping against the two definitions was 95-98%, which means there should be no dispute around the impact on how we define patient populations. In this regard, Roger notes that Gregory Gores, editor-in-chief of Hepatology, said the journal believes this issue is over and will not accept more publications on the subject. The third item is the perceived stigma around the word “fat.” Roger quotes NASH kNOWledge founder and patient advocate Tony Villiotti, who points out that while we may describe a specific medical event as a myocardial infarction, the doctor still tells the patient "You had a heart attack." Similarly, the concept of “fat on the liver” will be essentially to explain what is going on to the patient, whatever the nomenclature says. This leads Laurent to discuss the paper on stigma presented at the conference which suggests that "fatty liver" is far less stigmatizing in general than "obesity" or "diabetes," and some specific nuances of the paper. When he is done, Scott and Roger comment on vastly different moments in history and regions in the world where obesity was actually considered a sign of something positive. This entire discussion leads Scott to remember a presentation on Eli Lilly's triple agonist retatrutide and the remarkable impact this class of drugs is likely to have on how we manage obesity, diabetes and liver disease. Roger notes that Altimmune and Merck/Hanmi have similar agents in development. He goes on to note that these drugs demonstrate levels of weight loss found with bariatric surgery and asks Laurent and Scott whether they believe the drugs will have impact similar  to surgery. Both say it is too early to tell. Louise follows this by mentioning a study showing that allied health professionals are proficient at motivating patients to lose weight, maintain that loss, and do so in healthy ways.Roger's wrap-up question asks what will be different at TLM2024 next year in San Diego. You'll have to listen to hear the answers.

This conversation between Scott Friedman, Laurent Castera, Louise Campbell and Roger Green covers the four panelists' general impressions of TLM2023, both the good and bad of it. Scott starts with a simple statement: “It was good to be at an AASLD that felt like an AASLD. Specifically, Scott is talking about the energy and excitement associated with the meeting. He also approves of Boston as a meeting location. Scott's meeting worst was the meeting app. The group elaborates on why they all agree. Laurent Castera agrees with Scott: bad app; excellent meeting with a great deal of colleague interaction. As a virtual attendee, Louise felt her own unique pain with the app. In addition, only 20% of sessions were live, and many were Zoom, which meant ‘Zoom in the US.' She describes this as the most disappointing meeting experience, and she notes that some people paid $1,200 for it. I make two other points: the patient tracks were broad in coverage and highly well-attended, and Saturday night's Diwali celebration. Scott, Laurent and I agree that the meeting was genuinely crowded and hot…but worthwhile. My final comment: tremendous excitement and anticipation about March 14, resmetirom's PDUFA date at the FDA.  

Hepatology researchers and key opinion leaders Profs. Laurent Castera and Scott Friedman join Louise Campbell and Roger Green in the final element of our review coverage of TLM 2023. This far-ranging conversation moves beyond MASLD/NAFLD and MASH/NASH to consider an array of topics.The episode starts with Roger asking the other guests for their general impressions of the meeting. Three key insights: 1.    "Pre-pandemic" levels of interaction and discussion among attendees2.     Online meeting app was a "fail", becoming a topic of conversation in its own right while fostering confusion3.    In the "frenzy" about the anticipated resmetirom approval and other MASH drugs approaching market,  we shouldn't overlook that patients with PBC will soon have two new exciting PPAR agents, elafibranor and seladelpar. As Scott notes, we also learned about promising modes of action for PSC so, overall, a promising meeting for rare cholestatic diseases. The rest of this discussion covers multiple topics, key among them:  ·      Impact of FGF-21 and FGF-19 agents on patients with compensated cirrhosis. Roger is optimistic that agents might provide improvement. Scott is more pessimistic because we do not have agents addressing the unique mechanistic challenges in cirrhosis vs. advanced fibrosis. Both agree that agents on the horizon can buy time until curative or regressive medications arrive. ·      AI-based analysis. Roger bridges to Stephen Harrison's presentation of HistoIndex analysis of resmetirom that produces an estimate of 54% efficacy vs. 34% placebo. He comments that given this analysis and that bariatric surgery studies tell us fibrosis regression may take five years, the FDA one-year standard might be so stringent as to be misleading. ·      Bariatric surgery. Laurent refers to a presentation from Phillippe Mathurin's group demonstrating that in patients post-bariatric surgery, MASH resolution and fibrosis regression clearly lead to improved outcomes. ·      NITs. Laurent discusses a poster from a multi-country 16,000-patient cohort that did not confirm liver stiffness as leading to a decline in MALO over a two-year period but anticipates more robust findings over time. ·      VCTE-based analysis. Louise discusses two posters with analyses based on FibroScan. The first, from the Virginia Commonwealth University and the VA, found that liver stiffness correlates with success in liver transplant and that CAP can predict the risk of future MI in these patients. She notes that CAP of 270 served as "its own parameter" in predicting time to mortality. ·      Nomenclature. Roger notes that a Saturday morning session resolved the two most pivotal outstanding issues about the effect of nomenclature change on scientific development. FDA signaled that the agency views old and new nomenclature terms as interchangeable. NIMBLE and LITMUS analysis determined that patient mapping is also interchangeable.·      Impact of triple-agents. Presentations at this conference confirm that triple agents addressing GLP-1, glucagon and GIP can have bariatric surgery-level impact on liver fat and reduce the entire disease burden. Interspersed between these topics are a range of insights on cirrhosis disease models, regulatory slowness in moving on from current conditional efficacy metrics, treater supply vs. patient demand, "stigma", and basic science. This is a high-level view of an information-dense conversation. Listen to learn more and hear all the details.  

  “Nothing can stop the man with the right mental attitude from achieving his goal; nothing on earth can help the man with the wrong mental attitude.”  -Thomas Jefferson. Mindset can be a deal breaker or a deal maker when it comes to achieving your fitness goals. In fact, it's the key to unlocking your health and fitness goals. As our guest today mentions on his website: Over 70% of the U.S population is either overweight or obese. Every day we see the newest ‘secrets,' fads, diets, and quick fixes. We see thousands of ways to improve our fitness and it becomes overwhelming. It's apparent that progress can seem nearly impossible to attain if your mind's not right! Today on the Strong By Design podcast, Scott Friedman speaks about how the right mindset creates motion and momentum in your life! "You're never going to be completely sure of everything that you do, but as long as you've trained yourself to overcome those little rationalizations you can do a lot with that." - Scott Friedman   Time Stamps   01:01 – Welcome to the ‘Strong by Design' podcast 3:15 - Get to know today's special guest, Scott Friedman 5:44 - Scott recounts how his passion fueled him to start his fitness career 13:45 - Taming negative thoughts: How do you overcome the 'little voice' in your head? 20:06 - The 3 M's: What is it and why it's okay to fall off the bandwagon? 32:33 - Scott talks about his pet peeves in the fitness industry 38:54 - From goal-oriented to process-oriented: Changing the way you live your life 44:00 - Nutrition baseline: Why tracking what you eat matters 50:49 - Scott shares what's new for him this 2024 59:04 - The Under Dog: Discover his journey to idolizing Tom Brady 1:02:00 - Where can you go to connect with Scott Friedman     Resources:  ScottSpeaksFitness.com  The Power of Progress Podcast   Connect w/ Scott: Facebook  Instagram   Connect w/ CriticalBench: Youtube Facebook Instagram CriticalBench.com StrongByDesignPodcast.com  

Join the dynamic conversation between Colton Trout, a seasoned entrepreneur, and Scott Friedman, the Founder and Lifestyle Development Mentor at Scott Speaks Fitness (rebranding to The Power of Progress). Scott is an expert in fitness, nutrition, behavior change, goal setting, routine creation, and helping people break down mental barriers to create a healthy lifestyle. In this eye-opening discussion, they share their experiences with a business coaching program, revealing invaluable insights on lead generation, the importance of media kits and contracts, and the power of personal branding. You'll discover the hidden gems of marketing, including Colton's unique approach and method to stand out and build genuine connections. But that's not all; the conversation extends into the realm of AI for video creation and networking, where they discuss the impact of artificial intelligence in content production. Scott mentions using AI to generate clips from podcasts and videos, ushering in a new era of content creation. Whether you're a budding entrepreneur or an experienced speaker, this conversation will equip you with the knowledge and motivation needed to scale your business and create a lasting impact in your industry. Dive into the world of marketing strategies and discover the secrets to thriving in the digital age. Join us as we delve into essential topics like why people fail at their goals, overcoming obstacles, the three keys to achieving your goals, and transitioning from emotional to logical thinking. Don't miss this insightful conversation. Subscribe now to Today's The Day for more in-depth discussions and leave a review to let us know your thoughts! Connect with Scott Friedman: - YouTube: https://tr.ee/pM1gjInt35 - Apple Podcasts: https://tr.ee/kVKlp6aE7e - Spotify: https://tr.ee/3TZuR8-8sq - Website: https://www.scottspeaksfitness.com/ Follow Scott on Social Media: - Instagram: https://www.instagram.com/scottfriedman24/ - Facebook: https://www.facebook.com/scottfriedman24/ Connect with Colton: -Website: https://www.ColtonTrout.net -Socials: https://www.flowcode.com/page/coltontrout

If you missed this year's Paris NASH meeting, you missed some exciting presentations featuring fresh, pivotal insights about Fatty Liver diseases and some new approaches to learning about this disease. For this episode From the Vault, we take a look back at what has by far been the most downloaded episode in the history of the podcast: S2-E46 - Highlights from Paris NASH 2021. Jörn Schattenberg and Stephen Harrison combine to provide a robust synopsis of the meeting while Roger Green asks a few questions and keeps the discussion in-bounds:10:20 – Jörn introduces Paris NASH and discusses some of its basics, followed by introduction of Session 1: Epidemiology and the Public Response14:07 – Stephen discusses potential for integrating home healthcare visits into clinical trials17:15 – Session 2: Clinical Aspects17:52 – “NASH does come in different flavors.” Are we thinking about NASH with sufficient granularity?20:32 – NASH pathogenesis and its link to other metabolic diseases21:32 – Session 3: Deep dive into fibrosis24:30 – Talk on “Innovations in imaging assessment in fibrosis” raises pivotal questions about advances we can make in cellular-level understanding26:57 – Talk from Scott Friedman on “Common mechanisms, molecular evolution and resolution of fibrosis in NASH” yields several key ideas28:45 – The importance of understanding stellate cell subtypes33:37 – Jörn and Stephen select some key moments from Day Two35:45 – Innovations in clinical trial bring researchers to consider competing risks and challenges in determining causes of mortality in NASH trials40:26 – Session 8, “Global NASH,” describes the size and scale of the NASH challenge around the worldIf you have questions or comments around the contents of this episode or the FDA workshop on NITs, drug development or any other themes addressed in this week, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.Stay Safe and Surf On!

Along with NASH-TAG, Paris NASH is one of two famously small, science-based and publicly available events every year for the liver community. Given the depth of topics and ideas explored in Paris, the event in its entirety would be nearly impossible to cover in a single conclusive episode. That said, the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) are joined by two presenting KOLs, Scott Friedman and Laurent Castera, for a neatly packaged conversation to capture some of the key dynamics of the meeting. Particularly, the group hone in on developments in the landscape around NITs.This conversation starts with a question from Louise about whether utilizing CAP would provide added insight in light of what the group has discussed around NITs in the preceding conversations. Laurent responds that CAP is more related to inflammation and steatosis than to fibrosis, and Scott agrees. Laurent suggests that MRI-PDFF would be an ideal test for addressing this issue, but it is not cost-effective for regular practice. Therefore, he uses VCTE measures, including CAP, because the numbers he provides are motivating to patients. Louise asks how activation of stellate cells depends on disease and Scott notes that most stellate cell activation is driven by inflammation, not fat. However, this raises two challenges: whether lipotoxic mediators drive fibrosis directly or act through inflammation and, more broadly, that current clinical tools for measuring fat are quite broad. On this point, Jörn notes that as the liver progresses toward cirrhosis, it loses fat and thus makes  the entire issue more complex. Roger raises the question whether patient compliance and adherence might be affected negatively by uncertainty about the meaning of results. The rest of this conversation centers around Scott's comment about the complicated impact of using GLP-1s and other incretins to treat obesity will have on Steatotic Liver Disease (SLD) and challenges in treating and assessing adequately.  This episode and its conversations cover a range of fascinating insights stemming from yet another impactful Paris NASH meeting. If you have questions or comments around Paris NASH, NITs or any other themes addressed, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.Stay Safe and Surf On!

Along with NASH-TAG, Paris NASH is one of two famously small, science-based and publicly available events every year for the liver community. Given the depth of topics and ideas explored in Paris, the event in its entirety would be nearly impossible to cover in a single conclusive episode. That said, the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) are joined by two presenting KOLs, Scott Friedman and Laurent Castera, for a neatly packaged conversation to capture some of the key dynamics of the meeting. Particularly, the group hone in on developments in the landscape around NITs.This wrap-up conversation starts with Roger asking the panelists what other important/intriguing questions we have not yet covered which arose in the meeting. Scott discusses interesting talks on genetics. Laurent concurs and adds that he was struck by a talk about pediatric NASH, which is more likely to be endogenous since these young patients do not consume alcohol, but also confounded by how pediatricians are trained (or rather, not trained) to conduct biopsies and otherwise assess patients. Jörn discusses a statistical method for comparing disparate options known as DOOR – Desirability of Outcome Rankings. Lastly, Louise and Roger raise a couple of additional questions. Listen on to hear what they are.This episode and its conversations cover a range of fascinating insights stemming from yet another impactful Paris NASH meeting. If you have questions or comments around Paris NASH, NITs or any other themes addressed, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com. Stay Safe and Surf On!

Along with NASH-TAG, Paris NASH is one of two famously small, science-based and publicly available events every year for the liver community. Given the depth of topics and ideas explored in Paris, the event in its entirety would be nearly impossible to cover in a single conclusive episode. That said, the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) are joined by two presenting KOLs, Scott Friedman and Laurent Castera, for a neatly packaged conversation to capture some of the key dynamics of the meeting. Particularly, the group hone in on developments in the landscape around NITs.This conversation starts with Scott discussing the session he shared with Fabio Marra which investigates the link between fibrosis and regeneration. Scott points out that the liver's ability to regenerate is unique among organs and a pivotal question for which a new answer arises every ten years, none of which turns out to cover the topic adequately. He goes on to note that injured livers are less likely to regenerate and that regenerative livers are less likely to create scar. He suggests that while we do not know which one comes first, the answer is likely to have broad implications not only for liver disease but also a range of other organs. In response to a question from Roger, Scott says he considers it more likely that regenerating liver tissue sends a message to break down scarring. This inclination is based on thorough experience of observing the natural history of treating viral hepatitis. Jörn asks about the degree to which the underlying etiology of disease causes this response. Scott states that the response is fairly common across etiologies but, as he notes, the devil is in the details.The rest of this conversation is devoted to Laurent and his session with Dr. Mark Muthiah about the use and limitations of NITs. This talk evolved from a case study about an individual patient. Laurent's point, in a nutshell, is that we need a range of tests depending on the question we are trying to answer – initial screening vs. staging vs. monitoring - but that the entire issue runs the risk of overwhelming front-line treaters who are not aware of these issues. In this context, he sites the value of FIB-4, and also its major drawback related to ages and cutoffs.  This episode and its conversations cover a range of fascinating insights stemming from yet another impactful Paris NASH meeting. If you have questions or comments around Paris NASH, NITs or any other themes addressed, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.Stay Safe and Surf On!

Along with NASH-TAG, Paris NASH is one of two famously small, science-based and publicly available events every year for the liver community. Given the depth of topics and ideas explored in Paris, the event in its entirety would be nearly impossible to cover in a single conclusive episode. That said, the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) are joined by two presenting KOLs, Scott Friedman and Laurent Castera, for a neatly packaged conversation to capture some of the key dynamics of the meeting. Particularly, the group hone in on developments in the landscape around NITs.This session starts with questions to Laurent from Jörn and Louise about his comments on NITs from the preceding conversation. Jörn concurs with Laurent's statements on the value of FIB-4, particularly if the provider conducts sequential tests. Louise asks whether we are looking solely at liver disease, given the high levels of non-liver mortality among patients with F1-F3 fibrosis. Laurent notes that the primary purpose so far has been to identify F3 and F4 NASH, but more recently methods such as FAST, MAST, MEFIB and MASEF, which was discussed on the podcast in S4E39, seek to define disease stages with greater specificity. He then goes on to discuss the importance of the context of screening on test performance. Laurent notes that in higher prevalence populations there will be a larger percentage of false positives. Thus, he notes, FIB-4 works well in initial screening based on strong NPV performance, but has less value in a disease-enriched population. This episode and its conversations cover a range of fascinating insights stemming from yet another impactful Paris NASH meeting. If you have questions or comments around Paris NASH, NITs or any other themes addressed, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.Stay Safe and Surf On!

Along with NASH-TAG, Paris NASH is one of two famously small, science-based and publicly available events every year for the liver community. Given the depth of topics and ideas explored in Paris, the event in its entirety would be nearly impossible to cover in a single conclusive episode. That said, the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) are joined by two presenting KOLs, Scott Friedman and Laurent Castera, for a neatly packaged conversation to capture some of the key dynamics of the meeting. Particularly, the group hone in on developments in the landscape around NITs.This conversation begins with Jörn discussing his topic from Paris NASH. His notes stem from a topic he received from the organizers: once a drug is available in the clinic, which test will you use to decide if the patient gets the drug. Jörn notes quickly that he will use neither biopsy nor FIB-4. He then notes that FAST was designed for this purpose, but that no current test makes sense today. Scott raises the parallel question: once you commit a patient to therapy, how will you determine whether the patient is responding or not? Jörn notes that most of the data we see today is aggregate, rather than the individual patient data we will need to assess how each patient performs on these tests. Laurent notes that there is not much data on this issue and then goes on to discuss the one study that does exist. He also describes a two-stage decline in test scores over time, with a more robust early decline and a slower decline later. That said, he questions whether the reduction in stiffness results from a decline in inflammation or fibrosis. As the conversation winds down the floor goes back to Scott and Jörn. Scott notes that while the question is interesting, declines in inflammation or fibrosis both correlate with improved outcomes. He also notes that currently developing fibrosis-specific markers like ProC3 may help answer this question. Jörn says that the answer he gave in the meeting is a form of “it depends” – in this case, possibly on the starting level of drug, whether the decline is early or late stage and the starting fibrosis level.This episode and its conversations cover a range of fascinating insights stemming from yet another impactful Paris NASH meeting. If you have questions or comments around Paris NASH, NITs or any other themes addressed, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.Stay Safe and Surf On!

Along with NASH-TAG, Paris NASH is one of two famously small, science-based and publicly available events every year for the liver community. Given the depth of topics and ideas explored in Paris, the event in its entirety would be nearly impossible to cover in a single conclusive episode. That said, the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) are joined by two presenting KOLs, Scott Friedman and Laurent Castera, for a neatly packaged conversation to capture some of the key dynamics of the meeting. Particularly, the group hone in on developments in the landscape around NITs.This episode begins with Scott discussing the session he shared with Fabio Marra which investigates the link between fibrosis and regeneration. Scott points out that the liver's ability to regenerate is unique among organs and the question of how it does so is readdressed seemingly each passing decade without clear explanation. He goes on to note that injured livers are less likely to regenerate than healthy ones and that regenerative livers are less likely to scar. While we do not know which of these phenomena comes first, the answer is likely to have a broad range of implications not only for liver disease but also a range of other organs in addition. Next, Laurent shares thoughts from his session with Mark Muthiah about the use and limitations of NITs. In a nutshell, Laurent explains why we need a range of tests to choose from depending on the question which we are looking for an answer. The reoccurring theme on the podcast around the importance of frontline education and training is addressed by Laurent here. Further, he underscores the value and simplicity behind FIB-4 as a simple frontline testing tool while also discussing its drawbacks. From here, Jörn and Louise ask relevant and interesting questions around what Laurent has discussed. Jörn moves on to discuss the question that goes once a drug is approved, which test will you use to determine whether a patient receives that therapy or not? Jörn promptly notes that he will use neither biopsy nor FIB-4 then comments that FAST was designed for this purpose, but doesn't rise to the level he would hope to find. Scott raises a parallel question that goes once you commit a patient to drug, how will it be determined that the patient is responding or not? The conversation continues to look into how to assess data at an individual level and learn more about how each patient variably responds to tests.For a wrap up question, Roger asks for any other important or intriguing questions yet to be covered that arose in the meeting. Scott shares some interesting talks on genetics, while Laurent adds that he was struck powerfully by a talk on pediatric NASH. Jörn goes a different direction and discusses a statistical method for comparing disparate options known as DOOR, or desirability of outcome rankings, and its effect on how to compare drugs and different options in unique patient situations.This conversation covers many more fascinating elements of another insightful Paris NASH meeting. Listen to the full episode and dive into this weekend's conversation to gain a richer understanding than can be described in this summary. If you have questions or comments around Paris NASH, NITs or any other themes addressed in this episode, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.Stay Safe and Surf On!

Welcome new listeners. We're highlighting one or our favorite episodes: The Great American Food System makes chicken nuggets that look like hearts, dinosaurs even Baby Yoda. And why not? Last year, American families spent more than $200 million on frozen nuggets in novelty shapes. In this episode, Jane and Liz talk to Scott Friedman, whose family invented the dinosaur chicken nugget, and explore why dino nuggets—and all sorts of fun-shaped foods—might deserve a little more respect. Sales and distribution by Lemonada MediaSee omnystudio.com/listener for privacy information.

Struggling with sticking to your goals and maintaining good habits? You're not alone! Join us today as we chat with Scott Friedman, fitness motivational speaker, fitness coach, and host of the Power of Progress podcast. In our conversation, we'll dig deep into the world of habits, discover why it's so difficult to maintain them and learn how to set bigger-picture goals to keep us motivated. Together with Scott, we'll explore the journey from merely wanting to achieve a goal to actually accomplishing it. We'll discuss the significance of identifying your goal, getting emotionally invested in it, and creating actionable steps to reach it. Moreover, we'll dive into the importance of understanding why you want to make a change and having a clear plan of action to follow. Lastly, we'll touch on how everyone's journey is unique and how seeking guidance from an expert can be the key to unlocking your potential. Don't miss our insightful conversation about the power of habits and why they take time to show results. We'll talk about the importance of hydration, momentum, and how small changes can snowball into a lasting impact. Scott will share his strategies for remembering why you are pursuing a goal and staying accountable to it. So come along, and let's learn to build and maintain better habits with Scott Friedman! In this episode, you will hear: Fitness behavioral change coaching Evolutionary response to laziness  The importance of personal help Building habits for lasting change  The power of saying yes  Building habits that stick The importance of persistence Subscribe and Review Have you subscribed to our podcast? We'd love for you to subscribe if you haven't yet.  We'd love it even more if you could drop a review or 5-star rating over on Apple Podcasts. Simply select “Ratings and Reviews” and “Write a Review” then a quick line with your favorite part of the episode. It only takes a second and it helps spread the word about the podcast. Supporting Resources: * The Power of Progress Podcast: https://podcasts.apple.com/us/podcast/the-power-of-progress-mindset-motion-momentum/id1626190855 * Scott's website: https://scottspeaksfitness.com/ * Scott on Instagram: https://www.instagram.com/scottfriedman24/ * YouTube: https://www.youtube.com/@powerofprogress Episode Credits If you like this podcast and are thinking of creating your own, consider talking to my producer, Emerald City Productions. They helped me grow and produce the podcast you are listening to right now. Find out more at https://emeraldcitypro.com Let them know I sent you.

Hi! This is Lexie of Read by AI. I read human-curated content for you to listen to while working, exercising, commuting, or any other time. Without further ado: Texas mall shooter shared extremist beliefs against Jews, women and racial minorities on apparent social media page by Brandy Zadrozny, Courtney Kube, Ken Dilanian, Erik Ortiz, Scott Friedman, Deon J. Hampton, Char Adams and The Associated Press with NBC News.

EP060 - This episode reveals the head-shaking realization that was brought to my attention by the one and only Scott Friedman from the Power of Progress Podcast when he unintentionally redefined the mission of Inspired By Impact and my very purpose in life.Here are the challenges we be tackling today:

This week on Surfing the NASH Tsunami, we are offering a co-host ‘roundtable' catch-up between Jörn Schattenberg, Louise Campbell and Roger Green. This is a fun, casual conversation that looks into first quarter highlights and a preview of what's to come in quarter two of 2023.In this conversation, Jörn recounts highlights from attending the 3rd Annual Liver Connect Conference organized by the Chronic Liver Disease Foundation. He enjoyed this meeting which encompassed the “latest and hottest on development” and being present for a powerful presentation by Scott Friedman. Scott shared interesting new concepts around ‘hot versus cold' fibrosis states and how these influence drug development and the way we think of liver science. Roger points out that combination therapy may be the course of action when dealing with inflammation and fibrosis simultaneously.If you enjoy the episode, have questions or interest around its contents and Fatty Liver disease, we kindly ask that you submit reviews wherever you download our discussions. Alternatively, you can write to us directly at questions@SurfingNASH.com.Stay Safe and Surf On!

This week on Surfing the NASH Tsunami, we are offering a co-host ‘roundtable' catch-up between Jörn Schattenberg, Louise Campbell and Roger Green. This is a fun, casual conversation that looks into first quarter highlights and a preview of what's to come in quarter two of 2023. Jörn recounts a productive trip to California where he attended the 3rd Annual Liver Connect Conference organized by the Chronic Liver Disease Foundation. He shares his highlights from the meeting, including a summary of a powerful presentation by Scott Friedman on ‘hot' versus ‘cold' fibrosis, cirrhosis, combination therapies and more. Louise speaks to the intensity involved in reviewing publication for FibroScan approval in primary care pathways in the UK. One benefit of the lengthy protocols that NICE considers is that it ultimately produces world-leading cost-benefit analysis. The group goes on to discuss how different systems contribute to the field through their different strengths. Roger uncovers a new metaphor for describing fatty liver disease and announces exciting plans for the podcast's 3rd anniversary special. Among a number of other insights emerging from this session, the Surfers also discuss what is happening in the space of drug development and impending approvals, the strength in allied health professionals and primary care pathways for fighting fatty liver.If you enjoy the episode, have questions or interest around its contents and Fatty Liver disease, we kindly ask that you submit reviews wherever you download our discussions. Alternatively, you can write to us directly at questions@SurfingNASH.com.Stay Safe and Surf On!

In today's episode you'll learn about how to be more consistent and build momentum in your health and fitness journey through mindset and discipline with my guest, Scott Friedman.Scott is a nationally accredited Personal Trainer, Fitness Nutrition Coach, and Behavior Change Specialist who has been in the fitness industry for years.He has worked with hundreds of clients and specializes in mentoring them on how to build long-term, sustainable habits using his key principles of mindset, motion, and momentum.Scott is a unique and engaging speaker, coach, and host of the Power of Progress podcast (make sure to subscribe!). He prides himself on understanding the needs of those who wish to change their lives. Through storytelling, personal experience, and a refreshingly honest take on the fitness and nutrition industry, Scott empowers and inspires his audiences and clients to take congruent action to achieve their goals. His authentic “grip it and rip it” style resonates with people and motivates them to take practical steps that improve their lives.You'll learn all about:What inspired Scott to enter the fitness industry and his "grip it and rip it" styleGoals vs. process-oriented objectives and lifestyle changesMotivation vs. disciplineSmall, consistent steps vs. changing everything at oncePerception and mindset for achieving results and how to shift one's mindsetWhy positive thoughts don't work unless you feel itWhy having specific goals is crucial for successHow to understand the needs of those who wish to change their livesStorytelling and public speaking to empower and inspire audiencesEpisode resources:Scott's website - scottspeaksfitness.comGet your free ebook Back to Basics - at this linkEmail Scott at scott@scottspeaksfitness.comDownload the Power of Progress podcast - Apple or SpotifyWatch the episode on video here

Hi Folks!  We are listening to P!NK's song "Walk Me Home". Here is the US February is a full month.  It is Black History Month and Valentines Day is a thing that seems to take over. So we are discussing how this song fits into this month.  Written by P!NK, Scott Friedman and Nate Ruess "Walk Me Home" is full of hope and empowerment. Tune into hear our thoughts.  Thanks for listening!Spotify PlaylistIntro/Outro Music:Upbeat Forever by Kevin MacLeodLink: https://incompetech.filmmusic.io/song/5011-upbeat-foreverLicense: http://creativecommons.org/licenses/by/4.0/

NASH-TAG 2023 proved to be a watershed moment for Fatty Liver disease as exciting drug development readouts, powerful academic work on non-invasive tests and the willingness to dive into the toughest questions aligned in Deer Valley, Utah. In this weekend's conversation series, Surfing NASH reviews its diverse coverage of the conference by showcasing key excerpts across six recordings with various KOLs, patient advocates and stakeholders.This conversation consists exclusively of an exchange between Donna Cryer and Roger Green. The session begins by Donna noting that while the data is cause for enthusiasm, she is concerned that this alone does not guarantee an inevitable approval. In addition to good data, she suggests, is the need for good regulatory science. As she points out, Intercept hit its endpoints in 2020, yet no approval was gained at the time. “Good regulatory science” is, in her words, conclusive, granular and contains a simplified message. Roger asks for an example of what might not constitute good regulatory science. This leads Donna to recall that the fireside chat, although titled regulatory, focused more on clinical trial designs than how to prepare for advisory committees, health technology assessments and Phase 4 trials. She notes that during this discussion, a good question surfaced regarding how equipoise will change once drugs are approved. The implication: what FDA is currently seeking in Phase 4 becomes unrealistic once drugs reach the market. At this point, Roger returns to Scott Friedman's comment about the “straitjacket of biopsy” and how that impacts thoughts around trial design and “proof.” Donna adds that real-world evidence is the up-to-date approach these days, and it will be available once we have more experience with the medicines. As the session winds down, Roger goes back to the adiponectin analyses predicting non-response as being his favorite part of the meeting and explains why. Donna shares that one of her favorite moments came when Claude Sirlin, a radiologist, asked how they can become more involved here. Roger responds that radiology may succeed biopsy as a “hard standard” of efficacy. In the final moments, Donna discusses some of the presented data and questions that embodied a public health perspective. 

NASH-TAG 2023 proved to be a watershed moment for Fatty Liver disease as exciting drug development readouts, powerful academic work on non-invasive tests and the willingness to dive into the toughest questions aligned in Deer Valley, Utah. In this weekend's conversation series, Surfing NASH reviews its diverse coverage of the conference by showcasing key excerpts across six recordings with various KOLs, patient advocates and stakeholders.This conversation includes analysis by Scott Friedman, Rachel Zayas, Jörn Schattenberg, Louise Campbell and Roger Green. Roger leads by asking the group to detail the “sit up and take notice” moment of the meeting. Scott immediately describes the “800-lb gorilla in the room,” the resmetirom data, which casts a positive light around everything within the meeting at large. He goes on to discuss other key points, namely, compelling results for other drugs in earlier stage trials and NITs. Rachel agrees with Scott, stating that “the narrative has changed.” She also mentions Mary Rinella's nomenclature talk and the discussion of combination therapies. Jörn praises the high energy level and well-rounded nature of the talks. Louise points to previously unpublished efruxifermin data from the HARMONY trial that suggested to her we can place drugs in primary care practices if we also ensure they have appropriate tools and tests to monitor patients.Scott underscores perhaps the most staggering number in the meeting: only 3% of patients treated for NASH are treated by a hepatologist. Jörn concurs with this observation, adding that this casts light on the importance of using the NITs at hand to identify patients. Scott then referred back to Will Alazawi's presentation on pathways and a brief presentation from Siemens evaluating four different test strategies in terms of lowest cost and highest prediction. Roger comments that the wealth of NIT data is actually starting to point to simple strategies for using them in clinical trials and treating patients. The uses may vary, but the paths seem clear. For Roger, Fagan's nomogram, which Mike Charlton presented, was the moment at which the paths became clear. He next asks Scott to describe what he considers most pivotal here. Scott goes on to discuss the need to identify non-responders better and figure out how to best manage them. Jörn agrees in the profundity of this analysis and, in that context, calls into question whether our definition of “response” might change from fibrosis regression to something more broadly metabolic. As the talk winds down, Louise notes that we have seen some promising data about combination therapies. Lastly, Scott notes that we have far more scientific ways to approach combination therapy than simply seeing what drugs a company has in its portfolio.

In the aftermath of the February 2021 winter storm that knocked out power to two-thirds of the state and killed more than 200 Texans, lawmakers and regulators vowed that the grid would not fail like that again. So, have they made good on their promise? Energy consultant and former advisor to the chair of the Texas Public Utility Commission Alison Silverstein and NBC 5 senior investigative reporter Scott Friedman join host Baylee Friday to explain the new regulations put in place to safeguard the grid and what still concerns them about the natural gas side of the industry.

For our look back at NASH-TAG 2023, Jörn Schattenberg and Roger Green are joined by Amy Articolo and Naim Alkhouri for a discussion which dives into the therapeutic efficacy of recently announced data on resmetirom, NITs, bariatric surgery and more. Adjoining this session is a bonus interview with Donna Cryer on her impressions and key takeaways which largely look into the movement of regulatory science. In combination, this two-part episode encompasses contrasting and thought-provoking perspectives on addressing the opportunities and challenges in moving the Fatty Liver field forward.Naim opens the first conversation by noting the positivity emitted, echoing Scott Friedman's position that momentum from Madrigal's emerging data on resmetirom animated the wider program. In addition, he highlights that granularity around Intercept's study of patient response to obeticholic acid (OCA) revealed improvements among the F3 population. For Naim, OCA is a drug he has envisioned to be applied toward advanced disease and serves undermet needs of F3 patients. He concludes that in the wake of these aforementioned results, there remains plenty of opportunity to improve and other biotechs “are still in the game” with the energy to back them.At this point, Jörn underscores the strong presence of academia and involvement of various consortia as further evidence of progress. Amy joins to comment on the vibrant and dynamic discussions around NITs and how to enrich trials. She suggests that the dialogue has reflected the advancements of the field and how work can be enhanced with collective contribution. This leads to thoughts on pharmacodynamic change and demonstrating value to payers. Roger distills a main idea: if only 24% of patients show a one-level regression of fibrosis in a given period of time, there is much to learn about the other 76%. Conversation continues around narrowing the indeterminate zone and improving biomarker concordance in NITs. After exploring considerations in moving beyond biopsy, the group investigates the role of bariatric surgery. While recognizing the validity of bariatric surgery as a treatment option, Naim points to a brighter future of preventative hepatology whereby action precedes BMI levels of 50 and higher. At the end of the session, Roger asks each panelist for one unexpected thing that might happen in the next year.In the following interview, Donna opens with a powerful statement: hope is not a strategy, and optimism is not inevitability. Specifically, she is determined to match the trajectory of regulatory science to that of the momentous energies emerging from clinical science. In doing so, relationships and open lines of communication are key for meeting agreed endpoints. Next, the two talk about addressing the indeterminate zone in a different context and opportunities for harnessing real-world evidence. As this conversation moves forward, it becomes clear that Donna is committed to connecting patients to care today, and not only after a drug approval. In closing, she fields the same question as the preceding panelists, but offers a very different answer. Surf on to find out. 

In Part 2 of our real time coverage of the highly anticipated NASH-TAG 2023 conference, friends of the podcast Scott Friedman and Rachel Zayas join Louise Campbell, Jörn Schattenberg and Roger Green to review key takeaways from Friday and Saturday in Deer Valley. Following this session, Jörn, Louise and Roger review high points from the Saturday night “Potpourri” and “Regulatory Fireside Chat” sessions. The final feature of this episode is an enthralling and exclusive interview with HistoIndex Co-Founder and Chief Scientific Officer, Dean Tai, who shares captivating data from an AI-assisted histologic assessment of Phase 2 trials on aldafermin and resmetirom.Scott opens the leading session with a concise summary of his highlights distilled from an event burgeoning with impressive moments. His main suggestion is that the positive momentum of the recent Madrigal announcement energized the wider program. Rachel echoes the idea that “the narrative has changed” as the field enters a promising New Year. Next, Louise points to her interest in the presentation of previously unreleased Phase 2 results from the HARMONY Trial on efruxifermin. And finally, Roger speaks to the evolving roles that NITs play in clinical trial and primary care settings. As analysis advances, Scott nails down an important question: what are the factors that distinguish the responders from the non-responders in the resmetirom trial? This leads the group down a compelling line of interrogation. The question also proves pertinent later in the episode as Dean teases tools to uncover the nuances of how and where these drugs act in the liver and beyond. Other topics explored in the opening session include insights on combination therapy, covert alcohol use, bariatric surgery, nomenclature, NITs, genetics and more.In the second conversation, Jörn, Louise and Roger dive deeper into Saturday's session. A major theme: the increasing focus on the role of bariatric surgery in liver disease. Jörn also underscores discussion around moving the field forward with an NIT that predicts outcome as an acceptable surrogate for conditional drug approval. Roger comments that addressing how drugs get used - not how they get approved - shifts focus from the needs of regulators to those of the payers.Lastly, Dean joins Jörn and Roger to investigate fibrosis dynamics on a continuous scale using AI-based analysis and quantification of NASH features for treatment efficacy. The main idea: highly-precise assessment of liver slides has arrived, sparking a spate of new questions surrounding therapeutic possibilities. It becomes clear that advancements in AI digital pathology are paving a path for an entirely new, imaginative line of thinking for the Fatty Liver field. Surf on to the full feature for more on this illuminating topic.This episode of Surfing the NASH Tsunami, including the accompanying discussion on zonal and liver-volume corrected analysis of fibrosis and steatosis, is sponsored by HistoIndex, the world's leading specialist in stain-free imaging for NASH clinical trials. HistoIndex is transforming diagnostic standards and drug development for NASH with its second harmonic generation based AI digital pathology solution.

In a monumental moment in the never-ending pursuit of putting a major dent in Fatty Liver disease, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. Madrigal's leadership intends to file for resmetirom's accelerated approval with the FDA in the first half of 2023. If approved, the drug may become the first NASH medication introduced to market, depending on the outcome and timing of Intercept Pharmaceuticals' refiling of obeticholic acid.To recognize this special occasion, Surfing the NASH Tsunami hosts its largest ever suite of panelists who react to the enthusiasm, synergy and implications surrounding the news. This conversation starts with Jörn Schattenberg investigating the impact that the use of a broad set of NITs in this study will have on NIT adoption and use in clinical patient treatment. Mazen Noureddin comments on how the use of NITs in clinical trials can reduce recruitment time and costs associated with the trials. Scott Friedman points out that as we strive to learn how to identify drug failures faster, FDA might require broad NIT use as part of that effort. As the conversation continues, Rachel Zayas and Scott jump into more basic scientific issues. Rachel asks whether there is synergistic effect between LDL lowering and the primary endpoints and what that means for the disease. Scott asks what the results tell us on two fronts: first, what does it tell us about the ability of fat lowering to regress fibrosis if THR beta has no direct antifibrotic effect. Second, what about this drug converts fat lowering into fibrosis regression when other drugs that can lower fat and maintain lower fat levels do not demonstrate antifibrotic effects? After more comments about the science of the trial, Michael Betel asks how quickly focus will shift from monotherapy to combination therapy given how many patients did not succeed with resmetirom monotherapy. Mazen notes that other therapies were administered to patients in this trial. As the session ends, Louise Campbell asks questions about semaglutide design and Mazen discusses benefits and trial opportunities for this drug.

In a monumental moment in the never-ending pursuit of putting a major dent in Fatty Liver disease, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. Madrigal's leadership intends to file for resmetirom's accelerated approval with the FDA in the first half of 2023. If approved, the drug may become the first NASH medication introduced to market, depending on the outcome and timing of Intercept Pharmaceuticals' refiling of obeticholic acid.To recognize this special occasion, Surfing the NASH Tsunami hosts its largest ever suite of panelists who react to the enthusiasm, synergy and implications surrounding the news. This final conversation starts with Roger Green following up on a couple of earlier comments. First, he notes the fact that in other diseases, a combination therapy can get approved before each element of monotherapy has been approved. Second, he notes that semaglutide's Phase 2 result, with 72-week effects on steatosis and NAS activity score but not fibrosis regression, aligns with Scott Friedman's earlier statement that not all fat lowering may mean the same thing in the liver. Jörn Schattenberg and Mazen Noureddin follow-up with other comments about NAS, fibrosis and lipotoxicity. This leads Jörn to note that there is already a second THR-beta in trial, from Viking Therapeutics, and asks what this trial might mean for Viking. Mazen cites Terns as another company with other drugs, including a THR-beta in the pipeline, and believes they will benefit as well. Scott asks what all this means for patients with cirrhosis. Rachel Zayas then discusses some of the development work her company is doing and how these results might affect her work and ability to raise resources. As the session winds down, Kris Kowdley describes one more way that the use of companion diagnostics against dose response and non-response will aid payers. For her final thoughts, Louise Campbell discusses how we might consider this a major anti-cancer advance given how the liver is implicated not only in HCC but also in non-hepatic cancers. Surf on to hear the diverse array of closing takeaways from the rest of the group. 

In a monumental moment in the never-ending pursuit of putting a major dent in Fatty Liver disease, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. Madrigal's leadership intends to file for resmetirom's accelerated approval with the FDA in the first half of 2023. If approved, the drug may become the first NASH medication introduced to market, depending on the outcome and timing of Intercept Pharmaceuticals' refiling of obeticholic acid.To recognize this special occasion, Surfing the NASH Tsunami hosts its largest ever suite of panelists who react to the enthusiasm, synergy and implications surrounding the news. This conversation is the first in a series which navigates the reactions of eight panelists, including Michael Betel, Scott Friedman, Kris Kowdley, Mazen Noureddin, Rachel Zayas and co-surfers Jörn Schattenberg, Louise Campbell and Roger Green. As each recalls their various reactions to the news, the group addresses several points. Mazen describes his relief that we now have a Phase 3 trial that achieves efficacy and safety goals. Scott follows up with his anticipation of increased enthusiasm and energy for the entire set of stakeholders. Michael, the patient advocate representative among the group, reacts with a question: are we ready? Comments from Kris and Jörn drive one interesting outlook: this is the second positive Phase 3 trial in terms of efficacy. Such results might clear the field for a simpler approval process. Additionally, Jörn notes an approval would be in consideration in the EU where EMA requires both NAS improvement and regression of fibrosis.From the entrepreneur's perspective, Rachel recalls her decision a couple of years ago to pivot her company from hepatocellular carcinoma to NASH as what she calls a “bet on science.” This statement aligns with Roger's persistent belief that this study will open the doors for more investment. Jörn and Mazen discuss some of the specific elements of patient screening and population that demonstrate the power of this study. As the session winds down, Roger shares an interesting observation: while the researchers have begun by talking about patients, in an earlier, separate conversation Donna Cryer began by talking about investors. 

In a monumental moment in the never-ending pursuit of putting a major dent in Fatty Liver disease, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. Madrigal's leadership intends to file for resmetirom's accelerated approval with the FDA in the first half of 2023. If approved, the drug may become the first NASH medication introduced to market, depending on the outcome and timing of Intercept Pharmaceuticals' refiling of obeticholic acid.To recognize this special occasion, Surfing the NASH Tsunami hosts its largest ever suite of panelists who react to the enthusiasm, synergy and implications surrounding the news. This conversation starts with Louise Campbell commenting on two specific benefits. First to mention is the fact that the multiple metabolic measurements "check a lot of boxes," as she puts it, in terms of liver disease. Second, she notes there is great benefit for patients now that caregivers can tell them “if diet and exercise does not work, there is something else we can do.” Mazen Noureddin agrees, but notes that for F3 patients, drug therapy should start on the first or second visit. He also discusses the value of Hispanic patients and ways to discuss efficacy. Jörn Schattenberg asks whether the relatively similar results at two dose levels build or defeat the case for two dose levels. Kris Kowdley states confidently that having two dose levels is a benefit that these results demonstrate.Louise asks how we can drill down into the patients that did not succeed, and Scott Friedman raises issues around payer response and precision therapy. He notes that it may also redefine use of placebo in clinical trials. Michael Betel asks what role bariatric therapies – notably surgery – might play in liver therapy and how we evaluate it. Through the rest of this session, Kris, Mazen and Roger discuss ways that the scope of data in this study and the rest of the Madrigal program will enrich scientific knowledge for years to come.

Yesterday, in a monumental moment in the never-ending pursuit of putting a major dent in Fatty Liver disease, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. Madrigal's leadership intends to file for resmetirom's accelerated approval with the FDA in the first half of 2023. If approved, the drug may become the first NASH medication introduced to market, depending on the outcome and timing of Intercept Pharmaceuticals' refiling of obeticholic acid.To recognize this special occasion, Surfing the NASH Tsunami hosts its largest ever suite of panelists who react to the enthusiasm, synergy and implications surrounding the news. Alongside regular Surfers Jörn Schattenberg, Louise Campbell and Roger Green are friends of the podcast, Michael Betel, Donna Cryer, Scott Friedman, Kris Kowdley, Mazen Noureddin and Rachel Zayas. This is an unmissable, full house discussion which surveys what is primed to be a momentous breakthrough for the field. Read the Madrigal press release and surf on to hear what is to be a memorable episode.

In the Season 3 NAFLD Year-in-Review  conversations series, Surfers Jörn Schattenberg, Louise Campbell and Roger Green embark on a string of interviews with a handful of Key Opinion Leaders who made headlines and advances in Fatty Liver disease in 2022. In this exclusive segment, Scott Friedman joins to discuss his perspective on what has been an eye-opening year for liver science. Scott prefaces this session with the idea that in the absence of an approved drug, the field has responded with an urgency to develop improved pathways and targets. This urgency is coupled with progressive efforts to modify and improve clinical trials and endpoints, and noninvasive markers to make those trials more streamlined and accessible. From here he introduces illuminating findings on genetic variants associated with protection from Fatty Liver disease. An attention-grabbing conclusion: rare germline mutations in the CIDEB gene conferred substantial protection from liver disease. Scott states the implications are twofold. This summons recognition of the power of genetics in uncovering new pathways. This also highlights the complexities of a disease featuring genetic variants that may variably contribute to the likelihood that a patient with obesity develops NASH. He suggests that broadly, the challenge in NASH is sifting through an enormous palette of drivers - be it genetic, derived from the microbiome, or attributable to diabetes and the consequences of metabolic syndrome. All of which influence how we decide to establish and prioritize strategies for the discovery of new therapeutic targets. Reinforcing his recent comment on the podcast that gene therapy has effectively arrived, he notes the speed by which genetic information can translate into real therapies. Continuing on the theme of scientific advancements, Scott points to papers emerging from the Columbia University lab of Robert Schwabe. The aim of the Schwabe lab is to understand the regulation of wound healing responses to chronic liver injury with a specific focus on how the activation of hepatic stellate cells (HSCs) promotes liver fibrosis and liver carcinogenesis. Scott raises a spate of compelling questions in response to Schwabe's interrogation and subsequent findings on functions of HSCs, the main source of liver fibroblasts, during hepatocarcinogenesis. He accredits the feasibility of these studies back to the emerging availability of single cell sequencing technologies. Once again, Scott reveals his acceptance that the “devil is in the details,” alluding to the back-and-forth switching capacity of particular cellular functions. By identifying the transcription factor that drives this switching to a protective role, Scott suggests there is potential to enhance the expression of that transcription factor using gene therapy. Whether we can realistically expect to change the behavior of cells in the setting of an injured liver through the manipulation of gene expression is something to look forward to. “The best is yet to come.”The group breaks into a brief discussion around the stepwise commercial progression and eventual success of Hepatitis C treatment. As the interview winds down, Scott returns to one last paper of interest stemming from his own laboratory and set to be published in the imminent future. The focus of the paper postulates stage-specific therapies as NASH develops. While admittedly “a long way off” from a clinical setting, this project framework injects Scott with invigoration to address possibly the largest unmet need of patients who have or are approaching cirrhosis. Surf on to his upcoming NASH-TAG talk for a more explicit demonstration of this unfolding story. 

The latter half of December marks the Surfing the NASH Tsunami annual NAFLD Year-in-Review. In Part 1 of this Season 3 finale, Surfers Jörn Schattenberg, Louise Campbell and Roger Green interview Scott Friedman, Hannes Hagström and Donna Cryer to discuss putting a dent in Fatty Liver disease in 2022 and beyond. This episode features compiled excerpts from our respective guest interviews. Each interview in its entirety will debut as this week's conversations, releasing Friday through Sunday.Surf on to hear the diverse and powerful perspectives provided by a handful of the field's Key Opinion Leaders who made headlines and advances in Fatty Liver disease in 2022.

Given the vast amount of information and insight from The Liver Meeting, this episode sought to identify and explore a few key highlights. The panel (Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Ken Cusi, Wayne Eskridge and Roger Green) addresses several topics from the program.This final conversation examines the diversity of populations with NASH and other ways we can learn from and about them. Naim begins by discussing work with pediatric NASH, specifically noting the shortcomings of NITs for these patients. Ken and Roger note the diverse forms of NASH, including both lean and pediatric, that are receiving increasing attention. Roger also recalls the SPLENDOR Study and what it tells us about the ability of bariatric surgery-driven 20% weight loss to regress fibrosis in non-cirrhotic patients. The group touches briefly on Scott Friedman's observation from last week's coverage about the impact of environmental factors on the microbiome and how that might affect these metabolic issues.Roger closes by asking the group for one thing, besides a drug approval, that will change how we think about or treat this disease in the next year. Surf on to discover their predictions.

Given the vast amount of information and insight from The Liver Meeting, this episode sought to identify and explore a few key highlights. Even so, there is more in this episode than a brief summary can capture. The panel (Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Ken Cusi, Wayne Eskridge and Roger Green) addresses several topics from the program:Wayne presents information from a survey Fatty Liver Foundation conducted with NAFLD patients. The study reported that very few patients received adequate information at time of diagnosis, and one in three do not even receive a specialist referral. This sparks general discussion on how to drive stronger provider-to-patient communication. The group goes on to consider the value of testing and standardized score computation in medical records, which can improve screening and provider education to patients. One challenge here: AST, which is a key test in its own right and as part of FIB-4, is part of the standard test battery only in the US.In the minds of the panelists, provider information and education is and will remain a major challenge. Laurent notes that in France, providers associated cirrhosis with alcohol consumption, but not diet. Ken suggests that getting primary care providers to associate cirrhosis with fatty liver is a key step to improving screening and education.Naim points to the open-label resmetirom study with cirrhotic patients as providing “very promising results” in a range of non-invasive tests. He shares his enthusiasm that so many of the emerging guidelines rely on the same cut points in NITs. He goes on to discuss a study in which he and others evaluated the impact of using these guidelines (FIB-4 cut points, VCTE as second step, T2DM and metabolic patients as targets). Naim notes that if applied appropriately, the paper estimated only 8% of the US population would have any need to be treated by a hepatologist, and perhaps only 4-5 million would require intervention with expensive medications.Laurent shares a prospective screening study on patients with diabetes located in primary care settings or diabetes clinics based in the US. Using NITs to screen for NASH and MRE to screen for advanced disease, they identified 65% with NAFLD, 14% with advanced fibrosis and 5% with cirrhosis. When 164 of these patients moved into biopsy, they identified 61% with NAFLD, 30% advanced NASH and 9% cirrhosis. Laurent contrasts these results to a similar study conducted in a French diabetes clinic-treated cohort. The panelists explore the implications of both studies in terms of how should screening be conducted today. Jörn notes that we must consider the incentive for a physician to screen or enroll a patient.Ken discusses advances in the use of PPARs, noting first the ongoing work with the pan-PPAR lanifibranor followed by Poxel's work with PXL-065. The latter is a deuterium-stabilized form of pioglitazone that generates greater activity of the r-enantiomer and less of the s-enantiomer.  These are linked to mitochondrial benefit versus weight gain, respectively.Naim calls attention to the failing performance of NITs in pediatric NASH. Roger recalls the SPLENDOR Study (discussed on Season 2, Episode 60) and what it reveals of the ability for bariatric surgery-driven 20% weight loss to regress fibrosis in non-cirrhotic patients. Panelists then briefly discuss Scott Friedman's observation from last week's coverage about the impact of environmental factors on the microbiome and how that might affect these metabolic issues.Roger closes by asking the group for one thing, besides a drug approval, that will change how we think about or treat this disease in the next year. Surf on to discover their predictions.

Over 7,000 in-person attendees from around the world convened at the 73rd Annual AASLD Liver Meeting for a lively and momentous event in Washington DC. Surfing the NASH Tsunami hosted two recording sessions throughout the event to discuss key takeaways. This conversation is a composite featuring impressions from both sessions.The first session features Scott Friedman, Jörn Schattenberg, Rachel Zayas and Roger Green. Jörn starts this conversation by discussing a presentation delivered by Mazen Noureddin on the developmental mitochondrial uncoupler, HU6. While mitochondrial uncouplers are not new, they are to the field of NASH. Jörn goes on to describe a short, 61-patient trial. The trial yielded large percentages of patients reducing their liver fat more than 30% – around 40% at the lowest dose and 71 or 72% at the two higher doses – and HbA1C in a medication that appeared safe in this two-month trial. Scott goes on to credit Gerald Shulman at Yale for his role in developing knowledge about mitochondria and the liver. Jörn and Roger then recall Marcus Ranney, the self-described mitochondrial fan and biohacker, who discussed his affection for and belief in the importance of mitochondria during his talk in Barcelona and a subsequent NASH Tsunami interview. As the conversation wraps up, Jörn raises the idea that a mitochondrial uncoupler might be a short-term intervention at the start of a longer therapeutic regimen. Scott notes that the idea of induction therapy vs. maintenance is gaining traction.The second part of this conversation comes from a session on the final morning featuring Stephen Harrison, Sven Francque, Jörn Schattenberg, Ian Rowe, Jeff McIntyre and Roger Green. Roger begins with discussion of the REGENERATE trial, a Phase 3 from Intercept for obeticholic acid in non-cirrhotic NASH. Arun Sanyal  presented a reanalysis of the results as a late-breaker on Monday. Roger describes the change in pathology-reading technology from the original analysis, in which the entire deck was distributed randomly between two readers. The two readers represented for the consensus and adjudication process in consideration. Slides where agreement could not be reached were not used. Roger reviews his take on the important elements of the results:Improved resolution of what now appears to be transitory LDL elevationsA slight drop in placebo performance and slight increase in high-dose performanceThe latter indicates the higher dose is roughly three times as effective as placebo instead of two-fold in the original analysis. Stephen continues to comment on the larger, vastly enhanced safety database in this study. Sven notes the study suggests there may be significant benefit in halting progression even in patients who do not regress. 

Looking at relationships between leaders and their teams and between employees, Andy Lopata questions Scott Friedman and Paul ter Wal on their theories of employee engagement. They both believe that if leaders ensure their employees have fun and enjoy their time at work, they will perform better and produce better results. Objectives and core values need to be defined and employees held accountable.  Changes in the workplace including hybrid working means that leaders have to listen and then act in response to what employees are looking for now. Mental health and wellness have become important issues since Covid.  With the move from a command and control model of leadership, empathy is now 90% of a leader's skill.  

Hearts. Dinosaurs. Baby Yoda. SpongeBob. The Great American Food System makes chicken nuggets in all these shapes and more. And why not? Our kids eat loads of them. Last year, American families spent more than $200 million on frozen nuggets in novelty shapes. In this episode, Jane and Liz talk to Scott Friedman, whose family invented the dinosaur chicken nugget, and explore why dino nuggets—and all sorts of fun-shaped foods—might deserve a little more respect.